@article {Rostas:2016:0730-0832:234,
title = "Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby",
journal = "Neonatal Network",
parent_itemid = "infobike://springer/jnn",
publishercode ="springer",
year = "2016",
volume = "35",
number = "4",
publication date ="2016-07-01T00:00:00",
pages = "234-239",
itemtype = "ARTICLE",
issn = "0730-0832",
eissn = "1539-2880",
url = "https://www.ingentaconnect.com/content/springer/jnn/2016/00000035/00000004/art00008",
doi = "doi:10.1891/0730-0832.35.4.234",
keyword = "CORTICOSTEROIDS, HYDROCORTISONE, BRONCHOPULMONARY DYSPLASIA, NEONATE, DEXAMETHASONE",
author = "Rostas, Sara E. and McPherson, Christopher",
abstract = "Bronchopulmonary dysplasia is a morbidity of prematurity with implications into adulthood on respiratory and neurologic health. Multiple risk factors contribute to the development of bronchopulmonary dysplasia leading to examination of various strategies of prevention. Systemic corticosteroids
are one prevention strategy with a large body of data, creating an ongoing controversy regarding the risks and benefits of therapy. Careful consideration of the available data along with the clinical characteristics of the individual infant is required before using this powerful therapy.",
}